On January 24, 2024, the Company and the Purchaser completed an Additional Closing (as defined in the SPA) by issuing a (i) Note with an initial conversion price of $0.56 per share in a principal amount of $815,217.39, which is convertible into shares of Common Stock beginning on the Issuance Date, as defined in the Note, (ii) a warrant to purchase up to 395,781 shares of Common Stock with an exercise price of $0.56 per share and (ii) an additional warrant to purchase up to 395,781 shares of Common Stock with an exercise price of $0.56 per share.
@DavidMWalker7 For 25 years David has been the voice calling out in the wilderness to make straight the way, to save the next generation from the burden of our debts.
News update on the GMO approval process. The MOA just held a GMO variety validation meeting on December 28th. Expectations are for GMO approvals to come out of this and sales to begin this planting season. $SEED
https://t.co/UQhZ6B36HM
Lab results from the $SEED nutritionally enhanced corn (NEC) we planted last summer. Fat content was more than double regular corn. Looking forward to large-scale planting next season!
$CO acquiring early stage Golden Meditech portfolio company Cellenkos for $664M cash and $1.375M equity. Cellenkos completed $15M Series A round just last fall. Smells rotten
We're looking forward to taking investor questions on our earnings conference call, our first one in several years. Lots of positive developments to discuss. We also announced a transition to quarterly reporting. $SEED
https://t.co/KAWh9eWiWa